middle.news
Actinogen Accelerates Alzheimer’s Trial and Secures FDA Guidance on Depression Program
5:13am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Actinogen Accelerates Alzheimer’s Trial and Secures FDA Guidance on Depression Program
5:13am on Monday 2nd of June, 2025 AEST
Key Points
XanaMIA phase 2b/3 Alzheimer’s trial enrolment accelerates with 35 new patients passing biomarker screening
FDA Type C meeting yields clear regulatory pathway for Xanamem’s major depressive disorder indication
World Health Organization grants the nonproprietary name ‘emestedastat’ to Xanamem
Manufacturing scale-up progresses with 15kg batch production advancing commercial readiness
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE